- You can view the full Opko Health Ratings Report.
- Use our health services section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Opko Health ( OPK) pushed the Health Services industry lower today making it today's featured Health Services laggard. The industry as a whole was unchanged today. By the end of trading, Opko Health fell $0.22 (-2.5%) to $8.58 on light volume. Throughout the day, 2,849,488 shares of Opko Health exchanged hands as compared to its average daily volume of 5,628,500 shares. The stock ranged in price between $8.51-$8.84 after having opened the day at $8.79 as compared to the previous trading day's close of $8.80. Other companies within the Health Services industry that declined today were: Arrhythmia Research Technology ( HRT), down 8.3%, Stereotaxis ( STXS), down 7.1%, American Shared Hospital Services ( AMS), down 5.7% and Digirad Corporation ( DRAD), down 5.1%. Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Opko Health has a market cap of $3.7 billion and is part of the health care sector. Shares are up 83.0% year to date as of the close of trading on Thursday. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow.
